8-KRegulation FD

INTUITIVE SURGICAL INC 8-K Report, Regulation FD Disclosure (Oct 31, 2018)

Filed October 31, 2018For Securities:ISRG

Summary

Intuitive Surgical Inc. (ISRG) announced on October 29, 2018, that the China National Health Commission has released a quota for major medical equipment imports through 2020, allowing for the sale of 154 new surgical robots in China. While the da Vinci Surgical Systems are eligible for inclusion in this quota, actual sales are contingent upon a lengthy hospital tender process and subsequent approvals. The company has indicated that it does not expect to sell any systems under this specific quota in 2018 due to the anticipated timing of these processes. Investors should be aware that the realization of these sales is subject to various uncertainties, including provincial approvals, competitive products sharing the quota, and potential tariffs on U.S.-manufactured medical equipment.

Key Highlights

  • 1China has set a quota for 154 major medical equipment imports, including surgical robots, to be sold through 2020.
  • 2Intuitive Surgical's da Vinci Surgical Systems are eligible to be sold under this new Chinese quota.
  • 3Sales under the quota are not guaranteed and depend on a hospital tender process and receiving associated approvals.
  • 4The company does not anticipate any sales under this quota to occur in 2018.
  • 5Potential headwinds for sales include provincial approvals, lengthy tender processes, tariffs, and competition.
  • 6This announcement provides insight into potential future revenue streams from the significant Chinese market, albeit with a delayed and uncertain timeline.

Frequently Asked Questions

The announcement is significant because China has opened a quota for 154 major medical equipment imports, including surgical robots, through 2020. This provides a potential pathway for Intuitive Surgical's da Vinci Systems to be sold in China, a large and growing market.

Intuitive Surgical does not expect to sell any systems under this quota in 2018. The process involves lengthy hospital tender procedures and approvals, suggesting that revenue generation from this specific quota is likely to commence in 2019 or later.

Key risks include the uncertainty of hospitals successfully navigating the tender process, obtaining necessary provincial approvals, potential competition from other robotic systems vying for a spot in the quota, and the impact of tariffs on U.S.-manufactured medical equipment.

No, the quota does not guarantee sales. While the da Vinci Surgical Systems are eligible, actual sales depend on hospitals completing a tender process, receiving approvals, and ultimately choosing to purchase the systems.